Press release content from Globe Newswire. The AP news staff was not involved in its creation.
130 years of Philips innovation, collaboration, and social responsibility
Royal PhilipsMay 12, 2021 GMT
May 12, 2021
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today celebrated 130 years of innovation, collaboration, and social responsibility. During its rich history since being founded on May 15, 1891, in Eindhoven in the Netherlands, the company has continuously reinvented itself to remain relevant to society. Today, Philips is a leading health technology company with a purpose to improve the lives of 2.5 billion people a year by 2030 through meaningful innovation.
Royal Philips: 130 years of Philips innovation, collaboration, and social responsibility
Amsterdam, the Netherlands -
Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today celebrated 130 years of innovation, collaboration, and social responsibility. During its rich history since being founded on May 15, 1891, in Eindhoven in the Netherlands, the company has continuously reinvented itself to remain relevant to society. Today, Philips is a leading health technology company with a purpose to improve the lives of 2.5 billion people a year by 2030 through meaningful innovation. The company s 130th anniversary is a celebration of the continuous innovation journey that has enabled Philips to positively impact the lives of so many people around the globe, said Frans van Houten, CEO of Royal Philips. It s also about looking forward - continuing to innovate, collaborate and live up to the highest standards of doing business responsibly and sustainably. We will
Amsterdam, the Netherlands –
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today celebrated 130 years of innovation, collaboration, and social responsibility. During its rich history since being founded on May 15, 1891, in Eindhoven in the Netherlands, the company has continuously reinvented itself to remain relevant to society. Today, Philips is a leading health technology company with a purpose to improve the lives of 2.5 billion people a year by 2030 through meaningful innovation.
“The company’s 130th anniversary is a celebration of the continuous innovation journey that has enabled Philips to positively impact the lives of so many people around the globe,” said Frans van Houten, CEO of Royal Philips. “It’s also about looking forward – continuing to innovate, collaborate and live up to the highest standards of doing business responsibly and sustainably. We will continue to team up with innovators, experts and society to help create new
(2)
Press Release
Hørsholm, Denmark (26 January 2021) - Allarity Therapeutics A/S ( Allarity or the Company ) today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the British variant ), at the Pathogen and Microbiome Institute at Northern Arizona University (NAU).
The virus variant was labelled Variant of Concern 202012/01 by Public Health England (PHE), an agency of the UK Department of Health & Social Care, in a publication on 21 December 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other Coronavirus variants. This variant has also been identified in the U.S. in several states.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential .
Allarity Therapeutics A/SJanuary 26, 2021 GMT
Press Release
Hørsholm, Denmark (26 January 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the “British variant”), at the Pathogen and Microbiome Institute at Northern Arizona University (NAU).
The virus variant was labelled “Variant of Concern 202012/01” by Public Health England (PHE), an agency of the UK Department of Health & Social Care, in a publication on 21 December 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other Coronav